March 24th, 2022 (Earnings Report)Dear Reader,We just identified several healthtech stocks that are expected to release earnings starting Today!If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Evelo Biosciences
Symbol: EVLO
Recent Price: $3.95
Average Analyst Price Target: $17.25 (336.71%)
Market Cap: $211.17M
Last Year's EPS: -$0.62
Consensus EPS Forecast: -$0.59
Expected Earnings Date: Mar 23 2022
Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on Evelo Biosciences (EVLO) in the Healthcare sector with a Hold rating and a price target of $ 6 (1 week ago).
TipRanks.com also reports that Evelo Biosciences currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.25 . The target pricing ranges from a high forecast of $28.00 down to a low forecast of $6.00. Evelo Biosciences (EVLO)’s last closing price was $3.95 which would put the average price target at 336.71% upside.Here are 3rd party ratings for EVLO:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Bottom 38% (156 out of 252)
--------------------------------------------------------------------------
Nyxoah
Symbol: NYXH
Recent Price: $19.68
Average Analyst Price Target: $35.25 (79.12%)
Market Cap: $507.69M
Last Year's EPS: -$0.41
Consensus EPS Forecast: -$0.29
Expected Earnings Date: Mar 23 2022
Recent Analyst Action: Adam Maeder, analyst at Piper Sandler, reiterates coverage on Nyxoah (NYXH) in the Healthcare sector with a Buy rating and a price target of $ 40 (1 week ago).
TipRanks.com also reports that Nyxoah currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $35.25 . The target pricing ranges from a high forecast of $40.00 down to a low forecast of $30.76. Nyxoah (NYXH)’s last closing price was $19.68 which would put the average price target at 79.12% upside.Here are 3rd party ratings for NYXH:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Buy, Bottom 31% (174 out of 252)
--------------------------------------------------------------------------
Sight Sciences
Symbol: SGHT
Recent Price: $14.77
Average Analyst Price Target: $35.00 (136.97%)
Market Cap: $698.73M
Last Year's EPS: -$0.2
Consensus EPS Forecast: ―
Expected Earnings Date: Mar 23 2022
Recent Analyst Action: Andrew Brackmann, analyst at William Blair, reiterates coverage on Sight Sciences (SGHT) in the Healthcare sector with a Buy rating and a price target of n/a (1 month ago).
TipRanks.com also reports that Sight Sciences currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $35.00 . The target pricing ranges from a high forecast of $43.00 down to a low forecast of $27.00. Sight Sciences (SGHT)’s last closing price was $14.77 which would put the average price target at 136.97% upside.Here are 3rd party ratings for SGHT:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Hold, Bottom 33% (170 out of 252)
--------------------------------------------------------------------------
Valeo Pharma
Symbol: VPHIF
Recent Price: $0.54
Average Analyst Price Target: $0.95 (75.93%)
Market Cap: $42.55M
Last Year's EPS: -$0.02
Consensus EPS Forecast: ―
Expected Earnings Date: Mar 23 2022
Recent Analyst Action: Andre Uddin, analyst at Research Capital, reiterates coverage on Valeo Pharma (VPHIF) in the Healthcare sector with a Buy rating and a price target of $ 0.95 (3 weeks ago).
TipRanks.com also reports that Valeo Pharma currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $0.95 . The target pricing ranges from a high forecast of $0.95 down to a low forecast of $0.95. Valeo Pharma (VPHIF)’s last closing price was $0.54 which would put the average price target at 75.93% upside.Here are 3rd party ratings for VPHIF:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
Hookipa Pharma
Symbol: HOOK
Recent Price: $1.71
Average Analyst Price Target: $10.25 (499.42%)
Market Cap: $93.52M
Last Year's EPS: -$0.46
Consensus EPS Forecast: -$0.57
Expected Earnings Date: Mar 23 2022
Recent Analyst Action: Roy Buchanan, analyst at JMP Securities, reiterates coverage on Hookipa Pharma (HOOK) in the Healthcare sector with a Buy rating and a price target of $ 6 (15 hours ago).
TipRanks.com also reports that Hookipa Pharma currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.25 . The target pricing ranges from a high forecast of $16.00 down to a low forecast of $6.00. Hookipa Pharma (HOOK)’s last closing price was $1.71 which would put the average price target at 499.42% upside.Here are 3rd party ratings for HOOK:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 38% (156 out of 252)
--------------------------------------------------------------------------
Mereo Biopharma Group Plc
Symbol: MREO
Recent Price: $1.19
Average Analyst Price Target: $10.00 (740.34%)
Market Cap: $138.63M
Last Year's EPS: -$0.8
Consensus EPS Forecast: -$0.07
Expected Earnings Date: Mar 24 2022
Recent Analyst Action: Joseph Schwartz, analyst at Leerink Partners, reiterates coverage on Mereo Biopharma Group Plc (MREO) in the Healthcare sector with a Buy rating and a price target of n/a (1 week ago).
TipRanks.com also reports that Mereo Biopharma Group Plc currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.00 . The target pricing ranges from a high forecast of $10.00 down to a low forecast of $10.00. Mereo Biopharma Group Plc (MREO)’s last closing price was $1.19 which would put the average price target at 740.34% upside.Here are 3rd party ratings for MREO:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 38% (156 out of 252)
